This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe.
Axicabtagene ciloleucel is made from the subject’s own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70 percent is targeted.
Kite Pharma, Inc. is the sponsor of this study.